This product is suitable for use with the?Maxpar? Metal Labeling Kits.?For metal labeling using Maxpar? Ready antibodies,?proceed directly to the step to Partially Reduce the Antibody by adding 100 ?l of Maxpar? Ready antibody to 100 ?l of 4 mM TCEP-R in a 50 kDa filter and continue with the protocol. Always refer to the latest version of Maxpar? User Guide when conjugating Maxpar? Ready antibodies.

Clone 93 can be used for blocking of CD16/CD32 interactions with the Fc domain of immunoglobulins, but is not the same clone as 2.4G2.

The 93 mAb is specific to the common epitope of CD16/CD32. Additional reported applications (for the relevant formats) include: immunoprecipitation¹ and blocking of Fc-mediated reactions in functional studies^2,4,23. It is useful for blocking non-specific binding of immunoglobulin to Fc receptors. For blocking of Fc receptors in flow cytometric analysis, pre-incubate the cells with purified anti-CD16/CD32 antibody (=1.0 ?g per 10⁶ cells in 100 ?L volume) for 5-10 minutes on ice prior to immunostaining. For highly sensitive assays, we recommend Ultra-LEAF? purified antibody (Cat. No. 101330) (Endotoxin <0.01 EU/?g, Azide-Free, 0.2 ?m filtered).

Maxpar? is a registered trademark of Standard BioTools Inc.

1. Personal communication (IP)
2. Oliver AM, et al. 1999. Hybridoma 18:113. (Block)
3. Brummel R and Lenert P. 2005. J. Immunol. 174:2429.
4. Terrazas LI, et al. 2005. Int. J. Parasitol. 35:1349. (Block)
5. Clements JL, et al. 2006. J. Immunol. 177:905.
6. Mohamed W, et al. 2010. Infect Immun. 78:3306. PubMed
7. Ouchi T, et al. 2011. J. Exp Med. 208:2607. PubMed
8. Kmieciak M, et al. 2011. J. Vis. Exp. 47:2381. PubMed
9. Yamazaki S, et al. 2012. PLoS One. 7:e51665. PubMed
10. Li J, et al. 2012. Arthritis Rheum. 64:1098. PubMed
11. Azuma M, et al. 2012. Oncoimmunology. 1:581. PubMed
12. Koon HW, et al. 2013. J. Vis. Exp. 68:4208. PubMed
13. Hegde VL, et al. 2013. J Biol Chem. 288:36810. PubMed
14. Huang J, et al. 2013. J. Immunol Methods. 387:254. PubMed
15. Dutow P, et al. 2014. J Infect Dis. PubMed
16. Fan Y, et al. 2014. J Exp Med. 211:313. PubMed
17. Huang HN, et al. 2014. Antimicrob Agents Chemother. 58:1538. PubMed
18. Takei S, et al. 2014. Vaccine. 32:3066. PubMed
19. Richardson ML, et al. 2014. PLoS Negl Trop Dis. 8:2825. PubMed
20. Cekanaviciute E, et al. 2014. J Immunol. 193:139. PubMed
21. Kimura T, et al. 2014. Int Immunol. 26:697. PubMed
22. Everad A, et al. 2014. Nat Commun. 5:5648. PubMed
23. Cenci E, et al. 2006. J. Leuko. Biol. 79(1):40-5. (Block)

1. Barvalia M, et al. 2022. Methods Mol Biol. 2508:147. PubMed
2. Chung EJ, et al. 2022. Aging (Albany NY). 14:7692. PubMed
3. McClellan BL, et al. 2022. STAR Protoc. 3:101357. PubMed
4. Zhu YP et al. 2018. Cell reports. 24(9):2329-2341 . PubMed
5. Chung EJ, et al. 2021. Int J Radiat Oncol Biol Phys. 110:526. PubMed

B cells, monocyte/macrophages, NK cells, neutrophils, mast cells, dendritic cells

1. Barclay AN, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Unkeless JC. 1989. J. Clin. Invest. 83:355.
3. Qiu WQ, et al. 1990. Science 248:732.